Table 3.

Longitudinal trend of ALT over time for distinct virologic trajectory patterns for patients with chronic HBV infection on NA therapy in the overall study cohort.

	Intercept (95% CI), log IU/L	Coefficient β (95% CI)
Class 1 (VL long-term suppressed)	3.95 (3.85, 4.05)∗∗∗	-0.0026 (-0.0034, -0.0018)∗∗∗
Class 2 (VL suppressed timely)	4.39 (4.29, 4.50)∗∗∗	-0.0108 (-0.0122, -0.0094)∗∗∗
Class 3 (VL persistent with moderate levels)	4.01 (3.88, 4.13)∗∗∗	-0.0007 (-0.0026, 0.0012)
Class 4 (VL persistent with high levels)	4.13 (3.96, 4.30)∗∗∗	-0.0006 (-0.0037, 0.0026)
Class 5 (VL suppressed slowly)	4.48 (4.35, 4.60)∗∗∗	-0.0085 (-0.0106, -0.0065)∗∗∗

Derivation and validation cohorts were combined according to the VL trajectories. 1,883 patients (out of 1,885, 99.89%) had longitudinal measurements of ALT for modelling. The longitudinal trends of ALT over time were assessed by linear mixed effects models with random intercepts and slopes. All linear mixed effects models were adjusted for demographics (including age, sex, and ethnicity). ∗∗∗p <0.001 (Wald test).

ALT, alanine aminotransferase; HBV, hepatitis B virus; NA, nucleos(t)ide analogue; VL, viral load.